Skip to content

Search Results

No Matching Results

    Recently Viewed


      HomeLatest newsTackling the world’s most urgent healthcare needs
      Nursing, climate and drug therapy

      Tackling the world’s most urgent healthcare needs

      Championing global health equity, advancing environmental health and empowering its employees to be their best are just some of the ways Johnson & Johnson is working to help improve the well-being of people around the world. The company’s 2021 Health for Humanity Report reveals just how far it’s come toward these ambitious goals.

      Share Article
      share to

      Improving the trajectory of health for everyone, everywhere might sound overly ambitious, but that mission is the driving force behind everything Johnson & Johnson does. It reflects a commitment outlined in Our Credo, the mission statement the company has followed since 1943: “We are responsible to the communities in which we live and work and to the world community as well.”

      In 2021, Johnson & Johnson launched its latest set of public commitments, known as the Health for Humanity 2025 Goals. These 21 goals represent the areas of corporate citizenship and sustainability where the company believes it can make the greatest impact—ranging from health equity to environmental health—and support 11 of the 17 United Nations 2030 Sustainable Development Goals (SDGs).

      “As the most broadly based healthcare company, our commitment to creating a healthier society is foundational to our business,” says Joseph J. Wolk, Executive Vice President, Chief Financial Officer, Johnson & Johnson. “How we deliver meaningful impact to human health is correlated with generating long-term business results, which are complementary to environmental, social and governance actions that create accountability and value.”

      The company has just released its 2021 Health for Humanity Report, which details the progress the company has made in the past year toward meeting those 21 goals—including supporting frontline healthcare workers, increasing access to crucial medications and achieving carbon neutrality at its facilities worldwide. Learn how far Johnson & Johnson has come this past year in its mission to make the world a better place.


      The goal: Support at least 1 million nurses, midwives and community health workers with skills, tools and growth opportunities by 2030

      Healthcare worker with patient

      The progress so far: More than 731,000 of these healthcare providers around the world have already been reached through the Johnson & Johnson Center for Health Worker Innovation, supported by the Johnson & Johnson Family of Companies and Johnson & Johnson Foundation.

      How Johnson & Johnson is making it happen: As the world’s largest and most broadly based healthcare company, Johnson & Johnson has a unique ability to advance health equity by creating stronger healthcare systems—and that begins with bolstering those on the front lines. Even before COVID-19 hit, the World Health Organization (WHO) projected a shortfall of 18 million health workers by 2030. Now, in the context of the pandemic, health workers are facing increased levels of burnout. Indeed, a review of studies published in 2021 in Frontiers in Public Health found that one in three healthcare providers is experiencing work-related physical and mental stress.

      To support these frontline caregivers and the organizations that care about them, the Center launched a global learning community called The Resilience Collaborative. The Collaborative’s Toolkit (designed to highlight evidence-based strategies that can be adapted, implemented and tested to improve health worker resilience) and the Resilience Message Program (a free, evidence-based and adaptable set of SMS messages intended to improve health worker resilience) help give health workers the knowledge and resources to not only recover from stress but also adapt and grow from it. Research shows that resilience can act as a buffer during high periods of stress and protect against burnout.

      So far, the Resilience Collaborative has reached people from nearly 300 organizations aiming to improve health worker resilience and well-being across 40 countries.

      The Center has also supported the digital training of more than 200,000 frontline health workers on COVID-19 response and vaccination through partners like the World Continuing Education Alliance, reach52, VillageReach and UNICEF. And its work with has supported the WHO in its efforts to provide real-time alerts on vaccine registrations, adverse event reporting, rumor tracking and more—all in an effort to help provide education and advice so that frontline health workers can focus instead on providing urgent treatments.


      The goal: Make our medication available to 700,000 people living with multidrug-resistant tuberculosis (MDR-TB) by 2025, potentially averting 6 million new MDR-TB infections

      Medical researcher in lab

      The progress so far: In 2021 alone, 137,000 patients received access to our medicine for MDR-TB, which is recommended by the WHO as a core component of all-oral drug-resistant TB (DR-TB) treatment regimens.

      How Johnson & Johnson is making it happen: Tuberculosis is preventable and curable—yet it remains one of the top causes of death worldwide, claiming 1.5 million lives in 2020 alone. Why the disconnect? In addition to a growing resistance to the most frequently used first-line TB medicines, the COVID-19 pandemic presented a two-year hurdle in diagnosing people living with TB and DR-TB and getting medicines to those in need. According to the WHO, only about one in three people with drug-resistant TB accessed treatment in 2020, a drop of about 15% from 2019. Among the most vulnerable people in need of medication: children.

      In 2021, Johnson & Johnson marked an important step toward making its medicine available to younger patients with MDR-TB when the WHO added the scored 20 mg pediatric formulation of the drug to the Essential Medicines and Essential Medicines for Children lists, which helps more than 150 countries prioritize medicines for their own national needs. This milestone built on prior health authority approvals of the 20 mg tablet as part of combination therapy for children with MDR-TB 5 years and older and weighing at least 33 pounds.


      The goal: Achieve carbon neutrality for all Johnson & Johnson operations by 2030

      Johnson & Johnson wind turbines in Cork, Ireland

      The progress so far: Currently, 52% of the electricity at the company’s facilities around the world is produced or procured from renewable energy sources such as wind and solar power, which helps reduce its carbon footprint.
      How Johnson & Johnson is making it happen: Healthy people need a healthy planet. In fact, research published in The Lancet shows that failure to address environmental risk factors threatens to undermine the last half century of gains in global health—a concern Johnson & Johnson has long understood. That’s why it continues to push for ways to improve the environmental footprint of its operations.

      In 2021, the company signed two Utility Green Tariff contracts in the U.S., as well as four new renewable power purchase agreements (one in North America and three in Europe). These agreements, which allow Johnson & Johnson to purchase electricity directly from a renewable energy generator, along with its prior renewable electricity efforts, are expected to provide the equivalent of 100% renewable electricity for the company’s operations in the United States, Canada and Europe by 2023.

      As a result of these agreements Johnson & Johnson Vision will be run with 100% renewable electricity and all ACUVUE® contact lenses are now produced with renewable electricity.

      That’s not all: In 2021, seven of the company’s facilities achieved the Leadership in Energy & Environmental Design (LEED) certification—meaning, among other things, that their buildings have a lower carbon footprint and use less energy and water than the standard—bringing its total number of LEED-certified facilities to 67.

      Learn more about the 2021 Health for Humanity Report

      Check out all of the progress Johnson & Johnson has made toward its social, economic and environmental goals.

      More from Johnson & Johnson

      Meet a nurse who leads clinical trials to find innovative cancer therapies

      Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.